A Rare Presentation of Carnitine Palmitoyltransferase II (CPT-2) Deficiency With Normal Acylcarnitine Profile in a 10-Year-Old Boy With Muscle Weakness and Bilateral Hearing Loss
Iranian Journal of Child Neurology,
Vol. 16 No. 4 (2022),
,
Page 65-74
https://doi.org/10.22037/ijcn.v17i1.27609
Abstract
Carnitine palmitoyltransferase II (CPT-2) deficiency is a rare and autosomal recessive disorder of long-chains fatty acids oxidation. Here, we report a 10-year-old boy with a bilateral hearing loss and a myopathic form of CPT II deficiency which was confirmed under molecular genetic test analysis. He was admitted to our hospital with unexplained headache, vomiting, and fever. Furthermore, he developed seizures, muscle weakness, neck stiffness and pain, mild respiratory distress, and icteric appearance. The laboratory test results also showed sever elevated levels of lactate dehydrogenase (LDH) and Creatine phosphokinase (CPK). He had also icteric appearance with unexplained hyperbilirubinemia. Further examinations revealed normal heart, liver without neurological disorders. Muscle pathological examination reported normal pathology without neuromuscular and mitochondrial disorders and storage diseases. Finally, molecular test analysis with next generation sequencing (NGS) revealed a homozygous pathogenic variant in the CPT-II gene, c.338C>T p. (Ser113Leu) which was correlated to CPT-II deficiency fatty acid oxidation disorder. Furthermore, we identified a homozygous pathogenic variant in the ADGRV1 gene, c.15736C>T p.(Arg5246*), which suggest the Usher syndrome type 2C and the reason for sensorineural hearing loss in this case. Our finding indicates that CPT-II can be associated with multiple symptoms and clinical features. Therefore, evaluation of CPT-II deficiency with molecular test analysis may be helpful in cases with unexplained icteric appearance, muscle weakness and rhabdomyolysis.
- Carnitine palmitoyltransferase II deficiency
- next generation sequencing
- muscle weakness
- Usher syndrome
- rhabdomyolysis
How to Cite
References
Kabbouche MA, Powers SW, Vockell AL, LeCates SL, Hershey AD. Carnitine palmitoyltransferase II (CPT II) deficiency and migraine headache: Two case reports. Headache. 2003;43:490–5.
Avila-Smirnow D, Boutron A, de Los Ángeles Beytía-Reyes M, Contreras-Olea O, Caicedo-Feijoo A, Gejman-Enríquez R, et al. Carnitine palmitoyltransferase type 2 deficiency: novel mutation in a Native South American family with whole-body muscle magnetic resonance imaging findings: two case reports. J Med Case Rep. 2018;12:249.
Ross B, Zucherberg AL,Geraghty MT. Carnitine palmitoyltransferase II (CPT II) deficiency presenting with hyperammonemia in an infant (Abstract). Am J Hum Genet Suppl. 1996;59:A379.
Fanin M, Anichini A, Cassandrini D, Fiorillo C, Scapolan S, Minetti C, et al. Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency. Clin Genet. 2012;82:232-9.
Sigauke E, Rakheja D, Kitson K, Bennett MJ. Carnitine Palmitoyltransferase II Deficiency: A Clinical, Biochemical, and Molecular Review. Laboratory Investigation. 2003;83:1543–54.
Wallace RA, Klestov AC, Kubler PA. Emotional distress induced rhabdomyolysis in an individual with carnitine palmitoyltransferase deficiency. Clin Exp Rheumatol. 2001;19:583–6.
Kottlors M, Jaksch M, Ketelsen UP, Weiner S, Glocker FX, Lucking CH. Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromuscul Disord. 2001;11:757–9.
Taroni F, Verderio E, Fiorucci S, Cavadini P, Finocchiaro G, Uziel G, et al. Molecular characterization of inherited carnitine palmitoyltransferase II deficiency. Proc Natl Acad Sci USA. 1992;89:8429–33.
Elpeleg ON, Hammerman C, Saada A, Shaag A, Golzand E, Hochner-Celnikier D, et al. Antenatal presentation of carnitine palmitoyltransferase II deficiency. Am J Med Genet. 2001;102:183–7.
Berkman N, Meirow D, Katzir Z, Bar-On H. Acute renal failure due to carnitine palmitoyltransferase deficiency. J Intern Med. 1993;233:295–7.
Villard J, Fischer A, Mandon G, Collombet JM, Taroni F, Mousson B. Recurrent myoglobinuria due to carnitine palmitoyltransferase II deficiency: Expression of the molecular phenotype in cultured muscle cells. J Neurol Sci. 1996;136:178–81.
Mongini T, Doriguzzi C, Palmucci L, Chiado-Piat L, Maniscalco M, Schiffer D. Myoglobinuria and carnitine palmitoyltransferase deficiency in father and son. J Neurol. 1991;238:323–4.
Malik S, Abhimanyu Paldiwal A, Sujit Korday C, Sudhir Jadhav S. Neonatal Carnitine Palmitoyltransferase II Deficiency: A Lethal Entity. J Clin Diagn Res. 2015;9:SD01–SD2.
I. T. Pediatric Neurology, Part III: Handbook of Clinical Neurology. 3rd series. Amsterdam: Elseiver; 2013. Disorders of fatty acid oxidation. In Dulac O, Lassonde M; :pp. 1675–84.
Gempel K, von Praun C, Baumkotter J, Lehnert W, Ensenauer R, Gerbitz KD, et al. Adult” form of muscular carnitine palmitoyltransferase II deficiency: Manifestation in a 2-year-old child. Eur J Pediatr. 2001;160:548–51.
- Abstract Viewed: 236 times
- pdf Downloaded: 0 times